That Face! DWTS’ Witney Carson Reveals 1st Photo of Son Kevin Leo

Meaningful moniker! Witney Carson shared her newborn son’s name, Kevin Leo McAllister, three days after she welcomed him into the world with husband Carson McAllister.

‘Dancing With the Stars’ Pros’ Baby Bumps

The Dancing With the Stars pro, 27, posted the first photo of her baby’s face on Wednesday, January 6, and revealed that he is named Kevin Leo to honor her late father-in-law, Kevin McCallister.

“Named after his grandpa who sent him down to us,” she captioned an Instagram snap of the newborn with a wooden name plaque with his middle name written on it. “Born on Jan. 3rd 2021 ✨ 7lbs. 2oz. 21” long!”

The So You Think You Can Dance alum added: “My little Leo, I love you more than words can express. You are the most precious gift. My life will forever be changed by your sweet spirit. Welcome to the world Leo 🦁.”

Carson’s father died in March 2018 after battling cancer for two years. Following his passing, the dancer paid tribute to her late father-in-law, noting how hard it would be to one day have children who would not know their grandfather.

DWTS’ Pregnant Witney Carson’s Baby Bump Photos

“Although it will be excruciatingly painful at times to live without him, we know he lives on around us being our guardian angel wherever we go,” she captioned a black-and-white photo of the couple with her late father-in-law at the time. “It’s hard not to think, why does my husband have to live without his dad? Why do my kids not ever get to know their Poppy? & then I remember the Plan of Salvation, to know we will see him again … and that gives me peace.”

The Utah native continued: “I know Kevin is getting our kids ready to come down to meet us — he’s probably spinning them around on the floor right now, over and over again until they cry of laughter! We know you’ll be there when we can’t see you or hold you — lift us up when we have moments of trouble and heartache. Our guardian angel. We love you Kev.”

The new mom announced the arrival of Kevin Leo on Monday, January 4, after having an “unexpected C-section” and 24-hour labor.

“We are all healthy and well,” she wrote alongside a photo of her and Carson’s hands holding their son’s fingers. “We are so grateful & we’ve been soaking up every moment with our perfect angel boy. Thank you for all the prayers!”

The professional dancer shared a video from the first 24 hours with the couple’s baby, including footage from the hospital and Carson holding Kevin Leo shortly after his birth.

Celebrity Couples Who Are High School Sweethearts

“Everyone tells you how special bringing life into this world is but you never know exactly what they mean until it happens to you. 😭,” she captioned the Instagram video on Tuesday, January 5. “This is my whole entire world.”

The new parents announced in July 2020 that they were expecting their first child together. The high school sweethearts, who started dating their senior year, tied the knot in January 2016, after a three-month engagement.

For access to all our exclusive celebrity videos and interviews – Subscribe on YouTube!

Source: Read Full Article

Catelynn Lowell Reveals She Was Pregnant, But Lost the Baby in November

Heartbreaking news. Catelynn Lowell revealed that she found out was pregnant with her fourth child last month, but days later suffered a miscarriage.

Stars Who Are Honest About Their Fertility Struggles

The Teen Mom OG star, 28, announced the pregnancy and subsequent loss on Tuesday, December 8, via Instagram, sharing a photo of her pregnancy test and pics of her and husband Tyler Baltierra.

“I WAS Pregnant and excited to share it with all of you and I am heartbroken to reveal that I lost the baby,” she wrote. “I am sharing this to let you know you are not alone. We are all in this together and everyone experiences pain, loss, and the recovery from it.”

The MTV star noted that she is “still in the thick of dealing with this loss as it was recent and all the emotional trauma that follows such a loss in an already horrifically hard year.”

Lowell thanked her fans in advance for their “prayers, love, and support,” adding that she is also here for anyone going through a similar situation.

“I opened up about this only to help those who are experiencing the same thing to know that there’s someone else every day experiencing this,” she added. “This was painful to share… but again, you’re not alone. 🙏💔.”

Every Time Catelynn Lowell and Tyler Baltierra Clapped Back on Social Media

The 16 and Pregnant alum shares daughters Novalee, 5, and Vaeda, 21 months, with Baltierra, 28. The couple are also parents to daughter Carly, 11, whom they gave up for adoption in 2009.

Lowell revealed that she found out three days before Thanksgiving that the couple were expecting another child. “We were so excited,” she told Champion Daily on Tuesday, before explaining that she lost the baby on Thanksgiving day.

“I started bleeding,” the TV personality said, which is when she lost the baby. “I was overwhelmed by sadness and felt my emotions.”

The Conquering Chaos author added: “No matter what, I believe that when a woman sees a positive test you automatically start getting excited. All of that came crashing down.”

Lowell, who previously suffered a miscarriage in 2017, explained that she is in a better headspace this time around to deal with the pain. (The reality TV star previously went to in-patient treatment in November 2017 after having suicidal thoughts).

“I can tell that the mental health work I’ve done has had a huge impact because I wasn’t overcome by anxiety, but I was just sad,” she said. “It was super early but, like I said before, it still hurts and all the excitement goes out the window.”

Rainbow Babies: Stars Who Had Children After Miscarriages

The Couples Therapy alum concluded: “I know that when the time is right it will happen and everything in life has a plan and a destiny. Now we have two beautiful angels watching over us and our children.”

The reality star previously spoke to Us Weekly in October 2019 about her plans to expand her family.

“When we do decide to have another child, we are hoping for a boy,” she exclusively said at the time. “If we are meant to have all girls, then that’s just fine too!”

She shared her ideal timeline for another little one, saying “we are thinking of having another when Vaeda is about 1 or 2 years old.”

For access to all our exclusive celebrity videos and interviews – Subscribe on YouTube!

Source: Read Full Article

Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.

In a surprising twist, a study by Dana-Farber Cancer Institute scientists has revealed for the first time that CH can—in the right context—confer a health benefit. That context is in the setting of allogeneic stem cell or bone marrow transplants. The researchers report today at the virtual 62nd American Society of Hematology (ASH) Annual Meeting that patients who received transplants from older donors with CH had a lower risk of relapse and longer survival compared with patients who got transplants from donors without CH.

“Because clonal hematopoiesis in the non-transplant setting is associated with adverse outcomes, we initially expected to see something similar in recipients of transplants from donors with CH,” said Dana-Farber’s Christopher Gibson, MD, who co-led the study with R. Coleman Lindsley, MD, Ph.D.. “However, we largely found the opposite: donor CH is actually associated with better survival in most transplant recipients due to a reduced risk of relapse from their underlying cancer.”

The term clonal hematopoiesis refers to a genetically distinct subpopulation, or clone, of blood cells that share a unique mutation. Its prevalence is low in younger people but is estimated to occur in 10-20% of the population over age 70.

The Dana-Farber scientists had previously shown that CH could be unknowingly passed from donor to recipient during transplantation. “The only way to detect CH is to perform genetic sequencing of blood, which is not a routine part of the workup for prospective transplant donors,” said Gibson. “We were the first to show that passing CH from donor to recipient can occur without causing a new leukemia to arise in donor cells, but our study was not powered to assess the impact on other outcomes. We’ve been working on the follow-up study ever since.”

They evaluated the impact of CH in donors aged 40 years or older on recipient clinical outcomes in 1,727 donor-recipient pairs. The investigators identified CH in 388 of the 1,727 donor samples. The most common mutations found in the donor samples were in the gene DNMT3A. Those mutations were specifically associated with the improved overall survival and reduced risk of relapse in transplant recipients. Other gene mutations found in the samples were not associated with the survival benefit.

“We are not yet sure why donor DNMT3A mutations reduce the risk of relapse, but our data suggest that they improve the immune activity of donor T cells, which are one of the most critical determinants of transplant efficacy,” said Gibson. This theory fits with data from the trial showing that transplant recipients who received the drug cyclophosphamide to prevent graft-versus-host disease did not benefit from transplants from CH donors. That was likely because cyclophosphamide eliminates donor T cells from the graft as a means of preventing chronic graft-versus-host disease. In all other patients, on balance, despite the higher risk of chronic graft-versus-host disease, the reduction in relapse outweighed that negative outcome and yielded better survival with the CH donors.

Source: Read Full Article

Massive dataset reveals which governments have best responded to COVID-19 pandemic

Are our political institutions up for the task of managing the COVID-19 pandemic and any possible future similar threats? A research team led by faculty at Binghamton University, State University of New York has compiled an extensive dataset tracking public health government responses to COVID-19 at national and subnational levels of government throughout the world.

The coronavirus pandemic provides a unique opportunity to evaluate the response of different types of government to a global crisis, according to Binghamton University Professor of Political Science Olga Shvetsova. Other types of catastrophic events, such as war and national disasters, affect select countries or regions and do not allow one to draw global comparisons.

“We are motivated by events to figure out what happened and is happening, and develop new understandings of how government works and politicians function and respond to crises,” Shvetsova said of the collaborative lab.

As the pandemic unfolded over the spring and summer, Shvetsova’s lab compiled a massive database comparing pandemic-related governmental policies in 64 countries on both the national and subnational levels, as part of the COVID-19 Protective Policy Index (PPI) project. The data runs from January through May 2020, and is publically available for researchers’ use, while data collection is underway for the period between May and November.

The lab began collecting data on March 12. Policies tracked by the database fall into multiple categories, including: international and domestic border closures, school closures, social gathering and social distance restrictions, lockdowns and curfews, medical isolation and quarantine, the restriction of nonessential businesses and services, states of emergency, and mandates requiring personal protective equipment.

In addition to political science professors and doctoral students with the department, the project has drawn colleagues from around the country and even around the world, including Canada, the United Kingdom and Russia. Undergraduate students joined the effort, too, as research assistants. The lab is collaborative, with members pitching in on data collection, brainstorming, writing and responding to requests during the peer review process.

“Pandemic policy-making is a truly global experiment in how different types of government work. It is a check on how resilient we are, and what the constitutional sources of that resilience are,” Shvetsova said of the ongoing pandemic research.

The data has already sparked two papers, with more in the pipeline. “Institutional Origins of Protective COVID-19 Public Health Policy Responses” will appear in an upcoming issue of the Journal of Political Institutions and Political Economy, and takes a global look at the advent of pandemic-related policies. Published in September by Canadian Public Policy/Analyse de politiques, “COVID-19 Policy Response and the Rise of the Sub-National Governments” compares the advent of policies in Canada and the United States, on both the federal and state/province levels.

The lab will continue to collect data on the pandemic for as long as it remains feasible. The team hopes to make another round of data, from May through July, available by the end of the year. Additional variables as well as more countries will also be added to the database.

Currently, the lab is writing and publishing work on incentives and disincentives for pandemic response in democracies, looking at the impact of governmental structure, political parties and the way governments are held accountable for the health of their populations. Other projects will likely emerge as data continues to accumulate.

Long-term, the coronavirus may offer a metric with which to judge the efficacy of different styles of government in responding to crisis. That would require reliable statistics that other disciplines are gathering: of the number of cases and deaths, along with strong mathematical epidemiological models of factors determining spread and mortality.

Source: Read Full Article

New research reveals why low oxygen damages the brain

Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.

“These powerful protein responders initially protect brain cells from low oxygen as expected, but we find that their prolonged activity leads to unintended collateral damage that ultimately impairs brain cell function,” said the study’s principal investigator Paul Tesar, a professor in the Department of Genetics and Genome Sciences at the Case Western Reserve School of Medicine and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics.

Defining the mechanism of brain-cell damage in low oxygen conditions provides an opportunity to develop effective therapies, including a class of drugs studied in their research that could inform future clinical approaches for many neurological diseases caused by low oxygen. The work also clarifies how the response to low oxygen causes disease in other tissues outside the brain.

Their research was published online Oct. 21 in the journal Cell Stem Cell.

The body’s response to low oxygen

With the dawn of an oxygenated atmosphere, a burst of multicellular life was possible, as oxygen could be used to produce the energy needed to support complex life functions. Given the requirement of oxygen for life, nearly all organisms evolved a mechanism to rapidly respond to low oxygen—a condition called hypoxia. The Noble Prize in Physiology or Medicine was awarded in 2019 for discoveries of how cells in our body sense low oxygen levels and respond to stay alive.

At the core of this ancient response are proteins called hypoxia-inducible factors (HIFs), which instruct the cell to minimize oxygen consumption and maximize their access to oxygen. In this way, HIFs can be thought of as valiant heroes attempting to protect and resuscitate cells in the immediate response to low oxygen.

Prolonged hypoxia causes dysfunction in many tissues. In particular, stem cells in the brain are impaired by hypoxia in many diseases, including stroke, cerebral palsy related to premature birth, respiratory distress syndromes, multiple sclerosis and vascular dementia. Even the significant neurological damage caused by COVID-19 is attributed to hypoxia.

Until now, the precise causes of cell malfunction due to low oxygen were unknown.

The dark side of the hypoxia response

In this study, researchers developed a new approach to closely study how the hypoxia responder proteins function. By comparing how they work in brain-stem cells with other tissues, such as heart and skin, the scientists confirmed that the hypoxia responder proteins perform a beneficial function to promote cell survival in low oxygen in all tissues. However, these same hypoxia responder proteins had a previously unappreciated dark side, as they also switched on other cellular processes outside of the core beneficial response.

The team then demonstrated that this additional—and previously unknown—response is what impaired brain-stem cell function. This suggests that, while hypoxia responder proteins evolved to promote cell survival in all tissues of the body in low-oxygen conditions, their powerful effects can also have unintended consequences to disrupt cell function.

New opportunities for treating hypoxia damage

The authors tested thousands of drugs to try to restore brain-stem cell function to overcome the damaging effects of the hypoxia responder proteins. They discovered a group of drugs that specifically overcome the damage-inducing response, while leaving the beneficial response intact.

“One of the exciting avenues that stems from this work is identifying drugs that specifically target the damaging side of the hypoxia response while sparing the beneficial side,” said first author Kevin Allan, a graduate student in Case Western’s Medical Scientist Training Program. “This offers a new perspective on combating tissue damage due to hypoxia.”

Source: Read Full Article

Single-cell RNA sequencing reveals details about individual cells in pancreatic tumors

Led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and by HonorHealth Research and Innovation Institute, an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.

The study results were published today in the scientific journal Genome Medicine, a publication of Springer Nature.

Researchers used a relatively new technique known as single-cell sequencing to genetically identify cell types, and subtypes, that occur in pancreatic tumors, and identify the various cells in the tumor’s stroma, a substance surrounding the tumor that can hide the cancer from the body’s immune system.

While single-cell transcriptomics has been used previously to study the cellular composition of primary tumor tissues of pancreatic ductal adenocarcinoma (PDAC), this study also used the technology to profile individual cells from dissociated primary tumors and biopsies of metastatic tissues, those cancerous lesions that have spread throughout the body from the primary tumor.

This study was carried out in collaboration with investigators from Samsung Medical Center and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. Primary tumors and core needle biopsies of metastatic lesions from PDAC patients were sequenced using the Chromium single cell RNA-Seq platform.

“Single-cell transcriptome analysis can offer important clinical insights on individual cell subpopulations and provide clues for developing novel therapeutic strategies for both targeted therapies and immunotherapies,” said Haiyong Han, Ph.D., a professor in TGen’s Molecular Medicine Division and head of the institute’s Pancreatic Cancer Research Laboratory.

“Understanding the diversity and complexity of the PDAC tumor and stromal compartments in individual tumors may help identify unique intervention points and potentially inform treatment and maintenance strategies for patients with advanced disease,” said Dr. Han, the study’s senior author.

Distinct cell types and subtypes were identified in the analysis, including tumor cells, endothelial cells, cancer associated fibroblasts, and immune cells, and the expression levels of various genes in the individual cell populations correlated with patient clinical outcomes.

“Working with our partners and colleagues by utilizing the technology of singe cell sequencing, we can continue to learn more about the biology of pancreas cancer. These insights may potentially help us determine more treatment options for our patients,” said Erkut Borazanci, M.D., M.S., a medical oncologist and physician-investigator at HonorHealth Research and Innovation Institute, a clinical associate professor at TGen, and one of the paper’s authors.

Pancreatic cancer is an aggressive disease that carries a high mortality rate. It is the third-leading cause of cancer death in the U.S., following lung and colorectal cancers. In 2020, the five-year survival rate for pancreatic cancer is only about 10%, though that represents progress from the dismal 6% rate in 2014.

Next, researchers plan to use more advanced single-cell spatial transcriptomics analysis to further investigate the cellular relationships related to survival rates using real-time methods. Broader use of this technology could potentially guide the search for new agents to treat pancreatic cancer.

For more information about pancreatic cancer research studies at HonorHealth Research and Innovation Institute, please visit HonorHealth.com/research, call 480-323-1364 or email [email protected]

This research was supported by: the National Foundation for Cancer Research; SU2C-CRUK-Lustgarten Foundation Pancreatic Dream Team Research Grant (SU2C-AACR-DT-20-16); Baylor Scott & White Research Institute (BSWRI) and Translational Genomics Research Institute (TGen) Collaboration in Oncology Research; and the Korean Health Technology R&D Project (HI14C2640).

Source: Read Full Article

Study reveals type 2 diabetes remission can restore pancreas size and shape

In 2019, research revealed that achieving remission of type 2 diabetes by intensive weight loss can restore the insulin-producing capacity of the pancreas to levels similar to those in people who have never been diagnosed with the condition. Now, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year, demonstrates for the first time that reversing type 2 diabetes can also restore the pancreas to a normal size and shape.

“Our previous research demonstrated the return to long term normal glucose control, but some experts continue to claim that this is merely ‘well controlled diabetes’ despite our demonstration of a return to normal insulin production by the pancreas. However, our new findings of major change in the size and shape of the pancreas are convincing evidence of return to the normal state”, says Professor Roy Taylor from Newcastle University, UK, who led the research.

He goes on to explain, “Large amounts of insulin cause tissues to grow, or at least maintain their size. Normally, inside the pancreas the amounts of insulin present after a meal are very high. But in type 2 diabetes this does not happen. This new study suggests that achieving remission of type 2 diabetes restores this healthy, direct effect of insulin on the pancreas.”

Affecting 1 in 11 of the world’s adult population (415 million people), and on the rise, type 2 diabetes is caused by too much glucose (a type of sugar) in the blood due to the pancreas not producing enough insulin (a hormone which breaks down glucose into energy in the cells) together with insulin resistance.

Previous imaging studies have shown reduced size and abnormal shape of the pancreas in people with type 2 diabetes. But whether these abnormalities resulted from, rather than led to, the disease state was unknown until now.

In the study, 64 participants from the landmark Diabetes Remission Clinical Trial (DiRECT) and 64 age-, sex-, and weight- matched controls without type 2 diabetes were measured over 2 years for pancreas volume and fat levels, and irregularity of pancreas borders using a special MRI scan. Beta cell function—key to the body’s ability to make and release insulin—was also recorded. Responders (people in remission) were classified as achieving a glycated haemoglobin A1c (HbA1c) level of less than 6.5% and fasting blood glucose of less than 7.0 mmol/l, off all medications.

At the start of the study, average pancreas volume was 20% smaller (64 cm3 vs 80 cm3), and pancreas borders more irregular, in people with diabetes compared with controls without diabetes.

After 5 months of weight loss, pancreas volume was unchanged irrespective of remission (63 cm3 to 64 cm3 for responders and 59 cm3 to 60 cm3 in non-responders). However, after 2 years, the pancreas had grown on average by around one fifth in size (from 63 cm3 to 76 cm3) in responders compared with around a twelfth (from 59 cm3 to 64 cm3) in those who did not.

In addition, responders lost a significant amount of fat from their pancreas (1.6%) compared with non-responders (around 0.5%) over the study period, and achieved normal pancreas borders.

Similarly, only responders showed early and sustained improvement in beta-cell function. After 5 months of weight loss, the amount of insulin being made by responders increased and was maintained at 2 years, but there was no change in non-responders.

“Our findings provide proof of the link between the main tissue of the pancreas which makes digestive juices and the much smaller tissue which makes insulin, and open up possibilities of being able to predict future onset of type 2 diabetes by scanning the pancreas”, says Professor Taylor.

“All our research has been focused on type 2 diabetes which has developed within the last 6 years. Although some people with much longer duration diabetes can achieve remission, it is clear that the insulin producing cells become less and less able to recover as time passes. We need to understand exactly why this is and find ways to restore function in long duration type 2 diabetes.”

He concludes, “Type 2 diabetes is a simple disease occurring when an individual has more fat inside their body than they can cope with. The solution to the huge and growing problem of type 2 diabetes in the population lies in the hands of politicians. Legislation on supply of high calorie foods is essential to change our environment.”

Despite these important findings, the study has some limitations including that follow up was only for 2 years, and the observations were not pre-planned but made in retrospect.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, who funded the study, said: “Our landmark DiRECT trial has revolutionised thinking about type 2 diabetes—we no longer consider it to be a life-long condition for everyone, and know that remission is possible for some people. And we’re continuing to learn more about remission of type 2 diabetes every day. These new findings help to build a clearer picture of the biology behind remission, and how the health of the pancreas can be restored by weight loss.

Source: Read Full Article

Biomarker reveals how aggressive biliary tract cancer is in patients

The cancer called biliary tract cancer (BTC) is not the most widespread form of cancer. In western countries, about 1.6 in 100.000 gets the diagnose every year. It is, however, a very aggressive form of cancer.

The majority of patients with BTC are diagnosed with advanced disease and has an average survival of only 1 year from initiation of chemotherapy. With such narrow survival windows, it is crucial to improve our understanding of the disease.

Now, researchers from Biotech Research & Innovation Centre at the University of Copenhagen and Herlev and Gentofte Hospital along with collaborators from Rigshospitalet and Sygehus Lillebaelt have identified a biomarker that can tell doctors how aggressive a patient’s disease may be.

“We have found a biomarker that reliably predicts how aggressive a patients disease will evolve, which in the future could help doctors in the hospitals make the right decisions about chemotherapy for the benefit of each BTC patient,” says Jesper Andersen, Associate Professor at BRIC.

Biomarkers can used for more than the diagnosis

The researchers measured the levels of two inflammatory proteins and a biomarker commonly used in pancreatic cancer before and during chemotherapy in patients with advanced BTC and found that patients with higher levels of these markers before chemotherapy had a lower survival rate. Especially one protein called IL6 (interleukin-6) proved to be superior to the other markers in predicting those patients at greatest risk of death.

“A common misperception may be that biomarkers are mainly needed to diagnose a specific cancer type, but diverse biomarkers are also needed to guide clinical decision-making throughout each patients’ individual journey. These types of prognostic and predictive biomarkers deserve increased attention, in particular as they are playing important roles in the increasingly individualized management of more common cancer types”, says Jesper Andersen.

There are several markers to predict patients at greatest risk of death, however it was confirmed that the prognostic information provided by measuring IL-6 is not captured by other inflammatory markers already in routine clinical use. For instance, about 10 percent of the population does not express the marker that is normally measured (CA19-9) to predict the patient clinical outcome. Therefore, the course of disease cannot be predicted for these patients using CA19-9, for which IL-6 may be used instead.

Inhibiting IL-6 may improve response to chemotherapy

By inhibiting signaling of the protein IL-6 in a mouse model of human BTC, researchers discovered that the response of mouse tumors to chemotherapy significantly increased.

“Our data suggests that inhibiting IL-6 signaling may extend therapeutic benefit compared to chemotherapy alone. However, this will require careful evaluation in randomized clinical trial settings. Such a trial is currently ongoing at Herlev and Gentofte Hospital and results from this and potential future trials will contribute to our knowledge in regards to the potential of targeting the IL-6 pathway in patients with BTC”, says Jesper Andersen

Large sample size made possible through collaboration

Researchers studying BTC face a data-challenge since only 1.6 per 100,000 of Western populations are diagnosed with BTC annually. This makes it difficult to collect comprehensive amounts of patient data. Therefore, one of the key strengths of this study lies in the patient numbers attained and analyzed in this rare cancer demographic, amounting to 1590 serum samples from 452 patients with advanced BTC.

Furthermore, the study explores advanced BTC patients who represent the majority of patients at diagnosis, while the majority of previous BTC studies published to date have focused on early stage disease.

“It is imperative to increase representation of these patients with the worst prognosis in subsequent studies. These studies should also include longitudinal sampling throughout the patient’s clinical history, as we have done here”, says Jesper Andersen, group leader at BRIC.

The sample size achieved in this study was only made possible through the comprehensive collaboration between Herlev and Gentofte Hospital, Rigshospitalet and Sygehus Lillebaelt in Denmark.

Source: Read Full Article

New study reveals older adults coped with pandemic best

Adults aged 60 and up have fared better emotionally compared to younger adults (18-39) and middle-aged adults (40-59) amid the COVID-19 pandemic, according to new UBC research published recently in the Journal of Gerontology: Psychological Sciences.

Based on daily diary data collected between mid-March and mid-April of this year, the researchers found that older adults experienced greater emotional well-being and felt less stressed and threatened by the pandemic.

“Our findings provide new evidence that older adults are emotionally resilient despite public discourse often portraying their vulnerability. We also found that younger adults are at greater risk for loneliness and psychological distress during the pandemic,” says Patrick Klaiber, the study’s lead author and a graduate student in the UBC department of psychology.

For the study, the researchers analyzed data from 776 participants aged 18-91, who lived in Canada and the U.S. and completed daily surveys for one week about their stressors, positive events and their emotional well-being during the first several weeks of the pandemic. The time period was selected as it was likely to be the period of greatest disruption and uncertainty as local, provincial and state governments began issuing stay-at-home orders.

Klaiber says the difference in reported stress levels may be a result of age-related stressors and how well the different age groups respond to stress.

“Younger and middle-aged adults are faced with family- and work-related challenges, such as working from home, homeschooling children and unemployment,” says Klaiber. “They are also more likely to experience different types of ongoing non-pandemic stressors than older adults, such as interpersonal conflicts.”

Klaiber adds, “While older adults are faced with stressors such as higher rates of disease contraction, severe complications and mortality from COVID-19, they also possess more coping skills to deal with stress as they are older and wiser.”

The study also reveals older and middle-aged adults experienced more daily positive events—such as remote positive social interactions—in 75 per cent of their daily surveys, which helped increase positive emotions compared to younger adults.

Source: Read Full Article

Gigi Hadid Reveals a Bit of Her Bump & Why You Won't See More

During her pregnancy, Gigi Hadid is learning one of the first harsh rules about motherhood: Some people will care more about your child more than they do about all the other amazing things you create. Case in point, in preparing to promote Gigi Journal Part II, an art book she created with V Magazine, she wound up receiving tons of fan questions about showing off her baby bump, yet again.

“I’m so grateful for the positive comments and the questions and wanting just to know that we’re all good and safe and everything’s going great and I love you guys,” Hadid said on Wednesday in a long Instagram Live post to unveil the book.

“Obviously, I think a lot of people are confused why I’m not sharing more, but I’m pregnant through a pandemic,” she explained. “Obviously, my pregnancy is not the most important thing going on in the world. That’s a reason that I felt that it’s not really something that I need to share apart from with my family and friends. Obviously, a lot of people have lost lives due to coronavirus that was in the beginning of quarantine and still happening. And then we moved obviously into the reemergence of the [Black Lives Matter] movement, and I thought that our presence on social media should be used for that.”

This is a very mature, selfless way of explaining Hadid’s lack of pregnancy updates. Mine would have been more like, “I’ll post if I want to, so mind your own business,” only with more expletives. (Reason #798 Hadid is a social media star and I am not.)

But beyond the fact that the world is on fire and there are more important things to discuss than the shape of one model’s belly, Hadid also does want to maintain a bit of privacy during this very special time.

“I have been taking a lot of pictures of my bump and sending it to friends and family,” she said. “And it’s been really cute and exciting, and I’m trying to document it well because I’ve heard a lot of people say, make sure you don’t miss it. And I will be sharing stuff like that in the future. I just am not rushed to do it, and I feel like right now, I just want to experience it.”

Hadid spends her entire life presenting an image of herself for public consumption, so it’s pretty understanding if she wants a break from all that.

“I just don’t want to worry about waking up every day during my pregnancy and worry about having to like look cute or post something,” she went on.

We’ll always have the Bella twins for pregnancy bump pics.

Still, she made one tiny concession for curious fans who just want to see evidence of the life growing inside her. After she had previously explained about not looking pregnant on Instagram videos taking from the front, she discussed her love of loose, linen clothing, particularly the set from Holiday she was wearing. Then she unbuttoned the bottom of her shirt.

“OK, there’s my belly, y’all,” she said, revealing the top of her bump and leaving the rest out of view of the camera. “It’s there. It’s just that from the front, it’s different. … I’m taking my time with sharing my pregnancy, and you guys will see it when you see it.”

With that, she continued on with her original purpose, to show off Gigi’s Journal. Because, for real, can we please let a mom-to-be also have her career?

If Gigi and Zayn don’t have a name picked out yet, maybe they can get inspo from these wacky celebrity baby names.

Source: Read Full Article